A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer-Reference-Cited by-同舟云学术

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Published:2020-08-05 Issue:20 Volume:126 Page:4485-4497
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Zhang Tian¹^ORCID,Harrison Michael R.¹,O'Donnell Peter H.²^ORCID,Alva Ajjai S.³,Hahn Noah M.⁴,Appleman Leonard J.⁵,Cetnar Jeremy⁶,Burke John M.⁷,Fleming Mark T.⁸,Milowsky Matthew I.⁹^ORCID,Mortazavi Amir¹⁰,Shore Neal¹¹,Sonpavde Guru P.¹²,Schmidt Emmett V.¹³,Bitman Bojena¹⁴,Munugalavadla Veerendra¹⁴,Izumi Raquel¹⁴,Patel Priti¹⁴,Staats Janet¹⁵,Chan Cliburn¹⁶,Weinhold Kent J.¹⁵,George Daniel J.¹¹⁷

Affiliation:

1. Duke Cancer Institute Division of Medical Oncology Department of Medicine Duke University Medical Center Durham North Carolina

2. University of Chicago Chicago Illinois

3. University of Michigan Medical Center Ann Arbor Michigan

4. Johns Hopkins University Baltimore Maryland

5. University of Pittsburgh Pittsburgh Pennsylvania

6. Oregon Health and Science University Center for Health Portland Oregon

7. Rocky Mountain Cancer Centers Aurora Colorado

8. Virginia Oncology Associates Norfolk Virginia

9. Lineberger Comprehensive Cancer Center University of North Carolina–Chapel Hill Chapel Hill North Carolina

10. Ohio State University Comprehensive Cancer Center Columbus Ohio

11. Carolina Urologic Research Center Myrtle Beach South Carolina

12. Dana‐Farber Cancer Institute Boston Massachusetts

13. Merck & Co, Inc North Wales Pennsylvania

14. Acerta Pharma (a member of the AstraZeneca group) South San Francisco California

15. Division of Surgical Sciences Department of Surgery Duke University Medical Center Durham North Carolina

16. Department of Biostatistics and Bioinformatics Duke University Medical Center Durham North Carolina

17. Duke Clinical Research Institute Durham North Carolina

Funder

Acerta Pharma, a member of the AstraZeneca group

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33067

Reference40 articles.

1. Cancer statistics, 2019

2. Hallmarks of Cancer: The Next Generation

3. National Comprehensive Cancer Network. Bladder Cancer (Version 5.2018). Accessed December 29 2018.https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf

4. Elements of cancer immunity and the cancer–immune set point

5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches;Frontiers in Oncology;2024-04-02

2. The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers;Cancer Treatment Reviews;2024-04

3. Matched Analysis of Detailed Peripheral Blood and Tumor Immune Microenvironment Profiles in Bladder Cancer;Epigenomics;2024-01

5. Cardiovascular Adverse Events Associated With Second-Generation Bruton Tyrosine Kinase Inhibitor Therapy: A Systematic Review and Meta-Analysis;Clinical Therapeutics;2023-12